A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD

Xiaofei Wang1,2,3, Ao Hu1, Xiangyu Chen4,5, Yixin Zhang1, Fei Yu1,6, Shuai Yue7, Arong Li2,3, Junsong Zhang1,6, Zhiewei Pan7, Yang Yang7, Yao Lin7, Leiqiong Gao7, Jing Zhou7, Jing Zhao6, Fang Li9,10, Yaling Shi9, Feng Huang1,6, Xiaofan Yang1, Yi Peng1, Luoyang Tu1, Lilin Ye1, and Lilin Ye6,7

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). The neutralizing monoclonal antibodies (mAbs) targeting the receptor-binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and treat COVID-19. However, SARS-CoV-2 variants of concern (VOCs) profoundly reduced the efficacies of most of mAbs and vaccines approved for clinical use. Herein, we demonstrated mAb 35B5 efficiently neutralizes both wild-type (WT) SARS-CoV-2 and VOCs, including B.1.617.2 (delta) variant, in vitro and in vivo. Cryo-electron microscopy (cryo-EM) revealed that 35B5 neutralizes SARS-CoV-2 by targeting a unique epitope that avoids the prevailing mutation sites on RBD identified in circulating VOCs, providing the molecular basis for its pan-neutralizing efficacy. The 35B5-binding epitope could also be exploited for the rational design of a universal SARS-CoV-2 vaccine.

INTRODUCTION
The rapid spread of the COVID-19 pandemic has prompted the unprecedented development of anti-SARS-CoV-2 medical countermeasures, among which the most highlighted ones are neutralizing mAbs and vaccines. Indeed, several neutralizing mAbs have been approved under an Emergency Use Authorization for early therapy of COVID-19, including the first COVID-19-authorized mAb bamlanivimab, the REGN-COV2 cocktail (casirivimab and imdevimab), the combined use of bamlanivimab and etesevimab, regdanvimab, and sotrovimab. Additionally, effective vaccines have been developed and globally used, including inactivated vaccines, recombinant protein vaccines, adenosine-virus-based vaccines, and mRNA vaccines.

Though these neutralizing mAbs and vaccines have been developed to contain COVID-19 in the past 2 years, a major concern is the emergence of more transmissible and/or more immune evasive SARS-CoV-2 VOCs, which are antigenically distinct and become dominant in the COVID-19 prevalence over time. Indeed, the D614G variant became prevalent in the early phase of the pandemic and was associated with a higher transmission rate. As the thriving pandemic continued, a rapid accumulation of mutations was observed in SARS-CoV-2 and thus seeded the simultaneous appearance of a plethora of VOCs, which include but not limited to B.1.1.7 (UK; alpha variant), B.1.351 (SA; beta variant), P.1 (Brazil; gamma variant), and B.1.617.2 (India; delta variant).

In the RBD of SARS-CoV-2 spike protein, B.1.1.7 harbors a N501Y mutation and thus acquires enhanced binding of RBD to the human receptor ACE2. Along with the N501Y mutation, B.1.351 and P.1 develop additional K417N/T and E484K mutations. These mutations contribute to the immune escape of SARS-CoV-2 VOCs against many mAbs, including those already approved for clinical use (casirivimab, bamlanivimab, regdanvimab). These mutant VOCs also undermine humoral immune response elicited by the WT SARS-CoV-2 infection or vaccines targeting the WT SARS-CoV-2 protein sequence. Thus, highly potent and broadly neutralizing mAbs targeting multiple SARS-CoV-2 VOCs are urgently needed for emergency use.
In this study, we identified a neutralizing mAb 35B5 that broadly and potently neutralizes WHO-stated SARS-CoV-2 VOCs both in vitro and in vivo. Further cryo-electron microscopy analyses revealed that 35B5 binds to the RBD domain through a unique epitope and disrupts the spike trimer. Collectively, our findings on 35B5 discriminate it from previously identified neutralizing mAbs and highlight its potential application in the prevention and treatment of SARS-CoV-2 VOCs as well as the design of a universal vaccine against SARS-CoV-2 VOCs.
RESULTS
Isolation and characteristics of mAbs 35B5 and 32C7
To discover potent broadly neutralizing mAbs against circulating SARS-CoV-2 VOCs, we adapted a pipeline to rapidly isolate and characterize mAbs (Supplementary Fig. 1a). Given the vigorous SARS-CoV-2-specific memory B-cell response in individuals recovering from severe COVID-19 illness,22,23 cryopreserved PBMCs from these convalescent patients with WT SARS-CoV-2 infection were stained for memory B-cell markers (CD19, CD20, and IgG), from these convalescent patients with WT SARS-CoV-2 infection the surface plasmon resonance (SPR)-based optical assay. We binding to the RBD of SARS-CoV-2 virus were monitored using antibody capture assay and histological analysis. F. Viral titers in the lungs were measured by qRT-PCR and presented as RNA copies per milliliter of lung abrasive fluid. G. Gene expressions of cytokines and chemokines in the lungs were determined by qRT-PCR. H. Histopathological analysis of lung tissues. The data are representative of at least two independent experiments. *P < 0.05, **P < 0.01 and ****P < 0.0001. ns not significant. Error bars in (f) and (g) indicate SD.

whether 35B5 and 32C7 treatment ameliorated the pathological lung damage in the hACE2 mice infected with SARS-CoV-2. The transcripts of cytokines and chemokines (e.g., Ccl2, Cxcl1, Il1b, Il6, and Tnf), indicative of tissue inflammation, were greatly reduced in both 35B5- and 32C7-treated groups when compared to those observed in the mock group (Fig. 1g). Consistently, we found that 35B5 showed potent neutralizing capacity against the WT SARS-CoV-2, the D614G variant, the B.1.351 variant as well as the B.1.617.2 variant (Fig. 2c); whereas 32C7 showed slow-on/fast-off kinetics with a KD of 1.09 × 10^{-8} M (Fig. 1b). Consistently, these binding modes were further evidenced by enzyme-linked immunosorbent assay (ELISA) for SARS-CoV-2 RBD, with an EC50 value of 0.0183 μg/ml for 35B5 and an EC50 value of 0.1038 μg/ml for 32C7 (Supplementary Fig. 1e).

Potent neutralization capacity of mAbs 35B5 to SARS-CoV-2 virus in vitro and in vivo
We next investigated the neutralizing capacity of 35B5 and 32C7 against authentic WT SARS-CoV-2 infection in Vero E6 cells. Remarkably, we found that both 35B5 and 32C7 neutralized authentic SARS-CoV-2 virus in the low nanomolar range, with observed IC50 values of 1.55 ng/ml for 35B5 (Fig. 1c) and 5.63 ng/ml for 32C7 (Fig. 1d). We further assessed in vivo protection efficacy of 35B5 and 32C7 in the human ACE2 (hACE2)-expressing transgenic mouse model (ICR background) that is sensitized to SARS-CoV-2 infection.24 The hACE2-humanized mice were treated intraperitoneally with a single dose of 35B5 or 32C7 with 20 mg/kg at 6 h after intranasal infection with 4 × 10^7 PFU SARS-CoV-2. As control, infected mice of the mock group were administrated with an equal volume of PBS (Fig. 1e). At day 5 post infection, the viral loads in the lungs of the mock group surged to ~10^7 RNA copies/ml (Fig. 1f). By contrast, 35B5 and 32C7 treatment remarkably reduced the viral titers, with ~10^3 RNA copies/ml resulting 100-fold reduction and ~10^2 RNA copies/ml resulting tenfold reduction, respectively (Fig. 1f). In addition, we also determined
structure of the Fab region of 35B5 with the spike protein of SARS-CoV-2. Incubation of 35B5 Fab with the ectodomain of the spike protein S-2P,26 a stabilized spike mutant, severely caused the dissociation of the trimer and disrupted its structure quickly in vitro (Supplementary Fig. 2). 35B5 Fab even disrupted the ectodomain trimer structure of the spike S-HexaPro protein (S-6P),27 a more stable spike variant containing four additional proline substitutions (F817P, A892P, A899P, and A942P) from S-2P (Supplementary Fig. 2), suggesting that 35B5 harbors the potent dissociation activity toward the spike protein. Nonetheless, a few
of the S-6P particles were still found to maintain the triangular architecture27,28 after 35B5 Fab treatment for 3 min, which thereby allowed us to carry out cryo-EM analyses of the 35B5 Fab-S-6P complex. We successfully determined the structures of the 35B5 Fab-S-6P complex in three conformational states to the resolutions of 3.7, 3.4, and 3.6 Å, respectively (Supplementary Fig. 3 and Supplementary Table 1).

In the 35B5 Fab-S-6P complex structure of State 1, two RBD domains of the S-6P trimer are in the standard “up” conformations26 and are bound by 35B5 Fab (Fig. 3a). The other RBD domain is in the “down” conformation26 as that was found in the Fab-free spike trimers. In the 35B5 Fab-S-6P complex structure of State 2, each of the three RBD domains was in the “up” conformation and bound by a 35B5 Fab (Fig. 3a). In the 35B5 Fab-S-6P complex structure of State 3, although all the three RBD domains were bound by 35B5 Fab, only one RBD domain maintained the “up” conformation. The other two RBD domains were in unprecedented conformations, which we for the first time named as “releasing” conformations (Fig. 3a). Compared to the “up” RBDs, the two “releasing” RBD domains move out by 6.4 and 23.0 Å, respectively (Fig. 4f). The two “releasing” RBD domains generated large gaps with the adjacent NTD domains in the S-6P trimers (Fig. 3a), suggesting that the spike protein is undergoing structural dissociation.

35B5 targets a unique epitope for pan-neutralizing activity
The interactions of 35B5 Fab with the “up” RBDs are identical to those of 35B5 Fab with the “releasing” RBDs in the three states of the 35B5 Fab-S-6P complex. The interface covers a largely buried area of ~1029 Å² (Fig. 3b, c). The epitope in RBD for 35B5 is composed of 30 interacting residues including R346, F347, N354, A352, K444, Y449, N450, R466, I468, T470, N481, and F490, which form extensive hydrophilic interactions with 35B5 Fab in the structure (Fig. 3b–f). The corresponding paratope in 35B5 Fab consists of two heavy-chain complementarity determining regions (CDRH2 and CDRH3) and the heavy-chain frameworks (FRH1 and FRH3). The epitope of 35B5 on RBD is distinct from those of the previously identified four classes of neutralizing antibodies to RBD.29 The 35B5 Fab-binding surface on RBD is located at the site opposite to the receptor ACE2-binding surface,29–31 which is targeted by the class 1 antibodies, suggesting that 35B5 doesn’t directly block the receptor recognition for neutralization. Although the epitope of 35B5 Fab involves some regions of the epitopes of the classes 2 and 3 of antibodies (Fig. 4a, b and Supplementary Fig. 4a), the major 35B5-interacting residues, including the SARS-CoV-2-specific residues N354, T470, and N481 (Fig. 3b), which are not conserved in the spike proteins of SARS-CoV and MERS-CoV, are outside of the epitopes of the classes 2 and 3 of antibodies. Therefore, 35B5 targets a distinctive epitope to specifically neutralize SARS-CoV-2.

The SARS-CoV-2 VOCs contains several prevailing mutations on RBD, including N501Y (B.1.1.7 (alpha), B.1.351 (beta) and P1 (gamma)), K417N (B.1.351 (beta) and P1 (gamma)), L452Q (C.37 (lambda)), L452R (B.1.617.2 (delta), B.1.427/B.1.429 (epsilon), B.1.617.1 (kappa) and B.1.526 (iota)), S477N (B.1.526 (iota), T478K (B.1.617.2 (delta)), E484K (B.1.351 (beta), P1 (gamma), B.1.617.2 (delta), B.1.525 (eta) and B.1.526 (iota)) and F490S (C.37 (lambda)) (Fig. 5a). However, in the 35B5 Fab-S-6P complex structures, the residues N501, K417, L452, S477, T478, and F490 are not involved in the 35B5-RBD interactions. Only the residue E484 is located at the edge of the 35B5-RBD interface but not contacted by 35B5 Fab (Figs. 4c and 5b). Substitution of E484 by a lysine residue doesn’t generate severe structural collision with 35B5 Fab (Fig. 5c). It has been found that L452R mutation is of significant adaptive value to the B.1.617.2 variant (delta). However, L452 has the distance of more than 4.5 Å and 5.1 Å, respectively, to the residues T69 and Y60 of 35B5 Fab in the 35B5 Fab-S-6P complex structure (Fig. 5e), suggesting that the residue is not contacted by 35B5 Fab. Substitution for L452 by an arginine does not spatially affect the 35B5-Fab-RBD contacts. Instead, the mutation generates direct interactions with the residues Y60 and T69 of 35B5 Fab within 3 Å and likely forms two hydrogen bonds (Fig. 5e), suggesting that this mutation does not affect the binding affinity of 35B5 to RBD. Consistently, 35B5 has the comparable superneutralization efficiency to the B.1.617.2 variant as that to the wild-type virus (Fig. 2). Recently, it was found that the C.37 variant (lambda) contains the mutations L452Q and F490S.33 However, the mutations L452Q and F490S would not structurally affect the interactions of 35B5 Fab with RBD in the 35B5 Fab-S-6P complex structures (Fig. 5f, g), indicating that 35B5 might also exhibit potent neutralizing efficacy to the C.37 variant. Thus, the unique epitope of 35B5 on RBD subtly avoids the prevailing mutation sites, which provides the molecular basis for the potent pan-neutralizing efficacy of 35B5 to the SARS-CoV-2 VOCs.

Neutralization mechanism of mAb 35B5
To investigate the neutralization mechanism of 35B5, we analyzed the “down” RBD domain in the State 1 35B5 Fab-S-6P complex. In the density map of the State 1 complex, there were some residual densities closed to the “down” RBD domain. We further carried out local refinements on the “down” RBD. The local refinements generated a 4.8 Å density map and revealed that there is a 35B5 Fab contacting the edge of the epitope on the “down” RBD. The low resolution of the local refinement map suggests that the interaction between the 35B5 Fab and the “down” RBD is highly dynamic (Supplementary Fig. 4b–e). Structural modeling after the local refinements revealed that in contrast to the neutralizing mAbs BD-36827,28 and C002 recognizing the epitopes that are low resolution of the local refinement,32 the 35B5 Fab utilizes the CDRH regions to interact with the putative residues E340, T345, and E349 (Fig. 5f). The structural superimposition of the 35B5 Fab “up” RBD model with the “down” RBD in the 35B5 Fab-S-6P complex of State 1 or those in the Fab-free spike trimers27,34 reveals that the β-sheet and the linking loop of FRH1 of 35B5 Fab have severe structural clashes with the adjacent NTD domain of the spike protein (Fig. 4e), suggesting that upon the high-affinity binding of 35B5 Fab onto the “down” RBD, the spatial collisions between
Fig. 3 Cryo-EM structures of the spike protein S-6P complexed with 35B5 Fab. a The structures of the S-6P-35B5 Fab complex in three states. The S trimer is represented as surface. 35B5 Fab is shown in cartoon and colored in purple. The "down", "up", and "releasing" RBD domains are colored in blue, yellow, and red, respectively. The NTD domain of the S trimer is colored in deep gray. The SD1, SD2, and S2 domains are colored in light gray. The gap caused by 35B5 Fab between the "releasing" RBD and NTD domains is highlighted with dashed lines. b Interactions of 35B5 Fab with "up" RBD. The interacting residues within 4 Å in RBD are colored in cyan. The RBD-interacting regions CDRH2, FRH1 and FRH3 of 35B5 Fab are colored in yellow, blue, orange, and red, respectively. c The 35B5 epitope on RBD. The epitope residues are labeled as indicated. d-f Detailed interactions of the CDR (d) and FR regions (e, f) of 35B5 Fab with RBD. Hydrogen-bond and salt-bridge interactions are shown as blue and orange dashed lines, respectively.
35B5 Fab and the NTD domain potentially exert repulsion force onto the NTD domain to induce the conformational conversion of RBD from “down” to “up” conformation. When RBD is in the “up” state, the interactions between S1 and the adjacent spike promoter in the trimer are largely reduced, leading to the loose and unstable packing of the spike protein. Once all the 3 RBDs in the spike trimer are in “up” state, the spike trimeric particle tends to dissociate, which induces further outward movement of the “up” RBDs generated the releasing conformations in the State 3 35B5 Fab-S-6P complex. Thus, the 35B5 Fab-S-6P complex structures in these three states suggest that neutralization of SARS-CoV-2 by 35B5 is likely carried out in four sequential steps (Fig. 4g): 35B5 firstly binds to the exposed edge of the epitope to recognize the “down” RBDs of the spike protein; subsequently, binding of 35B5 imposes structural clashes on the NTD domain to drive the conformational changes of RBDs from “down” to “up”; next, the all “up” conformations of the RBD domains destabilizes the structure of the spike trimer and induces the outward movement and releasing of RBDs; finally, the released RBD domains cause the dissociation of the spike trimer.

The SARS-CoV-2 VOCs contain the most prevalent mutation D614G in the spike protein, which enhances infectivity by inserting a disordered loop (residues 620–640, the “630 loop”) between the SD1/CTD1 and NTD domains within a protomer to prevent premature dissociation of the G614 trimer.35 The residue D614 is not located in the epitope of 35B5 (Fig. 3b), thereby having no effects on its binding to the RBD domain. Although the D614G showed more up-RBDs, near 80% D614G particles contain at least one “down” RBD,36 suggesting that RBDs have an equilibrium on the transition between up and down states. 35B5
binding on the “up” RBD likely affects the dynamics of the RBD conformational transition. Moreover, upon binding to the “down” RBD domain, the capability of 35B5 to exert the repulsion force onto the NTD domain can probably counteract the enhancement effects of the 630 loop in the stability of the spike protein. Therefore, the unique epitope of 35B5 avoiding the prevailing mutation sites on RBD and the repulsion force of 35B5 exerting onto NTD during initial recognition renders its super-potent pan-neutralizing efficacy to the SARS-CoV-2 VOCs.

Cryo-EM structure of mAb 32C7
In contrast to 35B5, mAb 32C7 could not efficiently neutralize the SARS-CoV-2 VOCs. We also solved the cryo-EM structure of the Fab region of mAb 32C7 (hereafter named as 32C7 Fab) in complex with S-6P at a resolution of 2.8 Å (Supplementary Fig. 5 and Supplementary Table 1). The complex structure only contains one 32C7 Fab molecule, which is bound to a “down” RBD domain in the spike protein (Supplementary Fig. 6a–f). The 32C7 Fab-RBD interface only covers a buried area of ~935 Å², which is much less than that of 35B5 Fab (Fig. 3c, Supplementary Figs. 6g and 7b, d). In the S-6P-32C7 Fab complex structure, 32C7 Fab does not structurally clash with the NTD domain. Instead, 32C7 Fab interacts with the glycan moiety on the residue N165 of the NTD domain (Supplementary Fig. 6b). The binding surface of 32C7 Fab on RBD overlaps with the epitopes of the class 3 antibodies (Supplementary Fig. 6c), suggesting that 32C7 belongs to the classic class 3 family of neutralizing antibodies, which neutralizes SARS-CoV-2 via the Fc-mediated effector mechanism. Therefore, the neutralization of 32C7 to SARS-CoV-2 is likely carried out via the same mechanism. The mutations in the D614G and B.1.351 variants likely induce the conformational changes of the spike protein, which decrease the neutralizing activities of 32C7 to VOCs via the Fc-mediated effector mechanism.
DISCUSSION
In this study, we demonstrate 35B5 as a ultrapotent and pan-
neutralizing human monoclonal antibody against currently
circulating SARS-CoV-2 provided by experimental evidence in
vitro and in vivo as well as structural analysis. By contrast,
many mAbs such as casirivimab (REGN10933), bamlanivimab (LY-
CoV555), etesevimab (LY-CoV016), regdanivam (CT-P59), ABBV-
2B04 (2B04), and 32C7 in the study partially or entirely lose the
neutralizing activity against B1.351 and B1.617.2.6,16,37,38 The
mechanisms underlying the nanomolar broad neutralization by
35B5 at least involve three aspects: (1) broad interface and
extensive interactions between 35B5 and RBD endow 35B5 as a
totally poten epitope mAb; (2) proactive dissociation of the spike
trimer by structural clashes between 35B5 Fab FRH1 and spike
potent cross-epitope mAb; (3) no direct contacts between 35B5 Fab and
prevailing mutations of SARS-CoV-2 VOCs.
Previous works indicated that the ACE-binding surface is
partially exposed on the “down” RBDs in the tight- or loose-
closed spike trimer.27,34 The epitopes of some neutralizing mAbs
are also partially exposed on the “down” RBDs.29,39–42 The 35B5
Fab-S-6P complex structures in the three states we determined to
provide for the first time the direct structural evidence for the
possibility that the ACE2 or mAbs can approach the partially
exposed surface or epitope residues for initial recognition and
fulfill the conformational transformation of RBD. In previously
identified RBD-targeted mAbs, almost all class 1 mAbs interact
extensively with the residues K417 and N501. Most class 2 and
class 3 mAbs contact E484, and most class 3 mAbs interact with
L452.35B5 does not directly bind to these prevailing mutant
sites. In contrast to the Class 3 mAb S309

provided written informed consent. Blood samples were collected
from patients during their convalescence and the time between
symptom onset to sample collection was around 20 days. Healthy
donors were two adult participants in the study. Blood samples
were collected in cell preparation tubes with sodium citrate (BD
Bioscience). Then, peripheral blood mononuclear cells (PBMCs)
were isolated from blood samples using Ficoll (TBD Science),
washed with PBS, suspended in cell freezing medium (90% FBS
plus 10% DMSO), frozen in a freezing chamber at –80 °C, and then
transferred to liquid nitrogen. The study received IRB approvals at
Guangzhou Eighth People’s Hospital (KE202001134).

Single-cell sorting, RT-PCR, and PCR cloning
PBMCs were firstly incubated with Human TruStain FcX (Biole-
gend) at 4 °C for 30 min and then stained with biotin-conjugated
SARS-CoV-2 RBD protein (Sino Biological, 40592-V05H) at 4 °C for
20 min. Next, PBMCs were stained with PE-Cy7-conjugated streptavidin
e(bioscience), FITC-conjugated anti-CD19 antibody (Biolegend), PE-
conjugated anti-CD20 antibody (Biolegend), APC-
conjugated anti-human IgG (Fc) (Biolegend), APC-Cy7-conjugated anti-
CD3 antibody (Biolegend), APC-Cy7-conjugated anti-CD14 antibody
(Biolegend), APC-Cy7-conjugated anti-CD56 antibody (Biolegend)
and APC-Cy7-conjugated LIVE/DEAD dye (Life Tech-
ologies) at 4 °C for 30 min. All the stainings were performed in
PBS containing 5% mouse serum (wt/vol). For cell sorting, the
SARS-CoV-2 RBD-specific IgG

Materials and methods
Human samples
The COVID-19 patients enrolled in the study were admitted to
Guangzhou Eighth People’s Hospital (January to March 2020) and

Materials and Methods
Human samples
The COVID-19 patients enrolled in the study were admitted to
Guangzhou Eighth People’s Hospital (January to March 2020) and
2020 strain; GISAID: EPI_ISL_444969) was isolated from the sputum of a female infected individual and propagated in Vero E6 cells.

Surface plasmon resonance (SPR) assay
SPR experiments were performed using a Biacore T100 instrument (GE Healthcare, Uppsala, Sweden). All binding analyses were performed at 25 °C using HBS-EP + (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% Tween-20) as the running buffer. Experiments were executed following the previously described SPR protocol. Briefly, RBD protein was immobilized on the sensor chip CM5-type surface raising a final immobilization level of ~600 Resonance Units (RU). Serial dilutions of SARS-CoV-2 were injected in concentration from 10 to 0.125 nM. Serial dilutions of SARS-CoV-2 were injected in concentration from 120 to 7.5 nM. For the competitive binding assays, the first sample flew over the chip at a rate of 20 μl/min for 120 s, then the second sample was injected at the same rate for another 200 s. The response units were recorded at room temperature and analyzed using the same software as mentioned above.

ELISA
The ELISA plates were coated with 50 ng of SARS-CoV-2 RBD protein (Sino Biological, 40592-V08H) in 100 μl PBS per well overnight at 4 °C. On the next day, the plates were incubated with blocking buffer (5% FBS and 0.1% Tween-20) for 1 h. Serially diluted mAbs in 100 μl blocking buffer were added to each well and incubated for 1 h. After washing with PBST (PBS and 0.1% Tween-20), the bound antibodies were incubated with HRP-conjugated goat anti-human IgG antibody (Bioss Biotech) for 30 min, followed by washing with PBST and addition of TMB (Beyotime). The ELISA plates were allowed to react for ~5 min and then stopped by 1 M H2SO4 stop buffer. The optical density (OD) value was determined at 450 nm. EC50 values were determined by using Prism 6.0 (GraphPad) software after log transformation of the mAb concentration using sigmoidal dose–response nonlinear regression analysis.

Neutralization assay
An infectious SARS-CoV-2 neutralization assay was performed according to previous reports. Vero E6 cells were seeded in 24-well culture plates at a concentration of 4 × 10^4 cells per well at 37 °C for 24 h. For infection with authentic SARS-CoV-2 at an MOI of 0.005, 200 μl of diluted authentic SARS-CoV-2 and fivefold serially diluted SARS-CoV-2 were mixed in the medium with 2% FBS, and were then added into the Vero E6 cells. The culture supernatant was collected at 48 h post infection for focus forming assay and qRT-PCR. IC50 values were determined by nonlinear regression using Prism 6.0 (GraphPad).

Focus forming assay (FFA)
The virus titer was detected by FFA, which is characterized by its high throughput as compared to the traditional plaque assay. Briefly, Vero E6 cells were seeded in 96-well plates 24 h prior to infection. Virus cultures were serially diluted and used to inoculate Vero E6 cells at 37 °C for 1 h, followed by changed with fresh medium containing 1.6% carboxymethylcellulose. After 24 h, Vero E6 cells were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. Cells were then incubated with anti-SARS-CoV-2 nucleocapsid protein polyclonal antibody (Sino Biological), followed by an HRP-labeled secondary antibody (Proteintech). The foci were visualized by TrueBlue Peroxidase Substrate (SeraCare Life Science), and counted with an ELISPOT reader.

Protection against SARS-CoV-2 in hACE2 mice
All animal experiments were carried out in strict accordance with the guidelines and regulations of the Laboratory Monitoring Committee of Guangdong Province of China and were approved by the Ethics Committee of Zhongshan School of Medicine of Sun Yat-sen University on Laboratory Animal Care (SYSU-IACUC-2021-00432).

Viral infections were performed in a biosafety level 3 (BSL3) facility in agreement with recommendations for the care and use of laboratory animals. The hACE2 mice of the same sex were randomly assigned to each group. For infection, ICR-hACE2 mice were anesthetized with isoflurane and inoculated intranasally with 4 × 10^6 PFU SARS-CoV-2 virus (GISAID: EPI_ISL_402125). Six hours later, the infected mice received a single dose of 35BS (20 mg/kg) or 32C7 (20 mg/kg) or vehicle. And the H11-K18-hACE2 mice were intranasally challenged with 4 × 10^6 PFU of three subtypes SARS-CoV-2 virus (D614G, B.1.351, and B.1.617.2) per mouse, respectively. Four hours later, the infected mice received a single dose of 35BS (30 mg/kg) or vehicle. The lungs were collected at day 5 post infection for further assays.

Measurement of viral burden
For in vitro neutralization assay, RNA of culture supernatant was extracted by using TRIzol reagent (Invitrogen). For in vivo neutralization assay, lungs of SARS-CoV-2-infected mice were collected and homogenized with gentle MACS M tubes (Miltienyi Biotec, 130-093-235) in a gentle MACS dissociator (Miltienyi Biotec, 130-093-235). Then, the total RNA of homogenized lung tissues was extracted with RNeasy Mini Kit (QIAGEN, 74104) according to the manufacturer’s instruction. The extracted RNA was performed with quantitative RT-PCR (qRT-PCR) assay to determine the viral RNA copies by using a one-step SARS-CoV-2 RNA detection kit (PCR-Fluorescence Probing) (Da An Gene Co., DA0931).

To generate a standard curve, the SARS-CoV-2 nucleocapsid (N) gene was cloned into a pcDNA3.1 expression plasmid and in vitro transcribed to obtain RNAs for standards. Indicated copies of N standards were 10-fold serially diluted and proceeded to qRT-PCR utilizing the same one-step SARS-CoV-2 RNA detection kit to obtain standard curves. The reactions were carried out on a QuantStudio 7 Flex System (Applied Biosystems) according to the manufacturer’s instruction under the following reaction conditions: 50 °C for 15 min, 95 °C for 15 min, and 45 cycles of 94 °C for 15 s and 55 °C for 45 s. The viral RNA copies of each tissue were calculated into copies per ml and presented as log10 scale. The N-specific primers and probes were: N-F (5′-CAGTACGGAGACTTCGCTG-3′), N-R (5′-CGTACGGAGACTTCGCTG-3′), N-R (5′-CGTACGGAGACTTCGCTG-3′), N-F (5′-CGTACGGAGACTTCGCTG-3′), and N-R (5′-CGTACGGAGACTTCGCTG-3′). In each qRT-PCR experiment, both positive control and negative control of simulated RNA virus particles were included to monitor the entire experimental process and ensure the reliability of the test results.

Quantification of cytokine and chemokine mRNA RNA was isolated from lung homogenates as described above. Then, cDNA was synthesized from isolated RNA using HiScript III RT SuperMix for qPCR (Vazyme Biotech). The mRNA expression levels of cytokines and chemokines were determined by using ChamQ Universal SYBR qPCR Master Mix (Vazyme Biotech) with primers for IL-6 (forward: CCTCACTGGCTGAGATC; reverse: CAGGCTCAGGCATACAA), IL-1β (forward: ACTGAACTGAGATC; reverse: CACAGGAACAGCAGACC), IL-10 (forward: AGAGAGTACCCAGG; reverse: GGATGCTGACCACT), and CCL2 (forward: ACTGAGAAGGGTTTCTC; reverse: AGAGAGTACCCAGG; reverse: GGATGCTGACCACT), respectively. The results were normalized to GAPDH levels.

Histopathology
At day 5 post-SARS-CoV-2 infection, hACE2 mice were euthanized, and lungs were collected and fixed in 4% paraformaldehyde buffer. Tissues were embedded with paraffin and sections (3–4 mm) were stained with hematoxylin and eosin (H&E).

Production and purification of S-2P and S-6P proteins
The plasmids encoding the ectodomains of the SARS-CoV-2 S-2P and S-6P mutants were kindly provided by Dr. Junyu Xiao.
HEK293F cells were cultured in the SMM 293-TI medium (Sino Biological Inc.) at 37 °C with 8% CO₂. The S-2P and S-6P plasmids were transiently transfected into HEK293F cells using 25-kDa linear polyethyleneimine (PEI) (Polysciences) with the PEI:DNA mass ratio of 3:1 and 1 mg DNA for per liter of culture when the cell density reached 2 × 10⁹ cells per mL. At day 4 post transfection, the supernatants of the cell culture were harvested by centrifugation at 10,000×g for 30 min. The secreted S-2P and S-6P proteins were purified using HisPur™ cobalt resin (Thermo Scientific®) and StreptTactin resin (IBA). Further purification was carried out using size-exclusion chromatography with a Superose 6 10/300 column (GE Healthcare) in the buffer containing 20 mM HEPES pH 7.2, 150 mM NaCl, and 10% Trehalose. The Fab regions of the S-35B5 and S-32C7 were obtained after the digestion by papain for 40 min at 37 °C in a buffer containing 20 mM HEPES pH 7.2, 150 mM NaCl, 5 mM EDTA, and 5 mM L-cysteine. The obtained Fabs were purified with a Desalting column (GE Healthcare Life Sciences) to remove L-cysteine, and then further purified in a HiTrap Q column (GE Healthcare Life Sciences). The purified Fabs were collected and concentrated to 0.6 mg/mL.

Negative-staining analysis
For negative-staining assays, the S-2P, S-6P, 35B5 Fab, and 32C7 Fab proteins were diluted to 0.02 mg/ml in the buffer of 20 mM HEPES, pH 7.2, and 150 mM NaCl. In all, 2 μL of 35B5 Fab or 32C7 Fab was mixed with 2 μL S-2P or S-6P and incubated on ice for 3 and 10 min, respectively, or at room temperature for 30 min. The samples were loaded in the glow-discharged carbon-coated copper grids and stained with 3% uranyl acetate (UA). The prepared grids were examined using a Tecnai G2 Spirit BioTWIN transmission electron microscope (FEI) operated at 120 kV. Micrographs were recorded and analyzed using Digital Micrograph software with ×120,000 nominal magnification.

Cryo-EM sample preparation and data collection
In total, 2 μL of 5-6P (1.2 mg/mL) and 2 μL of 35B5 Fab or 32C7 Fab (0.6 mg/ml) were incubated for 3 min at room temperature and then loaded onto the glow-discharged Holy-carbon gold grids (Quantifoil, R1.2/1.3). The grids were washed using the buffer containing 20 mM HEPES, pH 7.2, and 150 mM NaCl. The washed grids were blotted using a Mark IV Vitrobot (Thermo Fisher) at 100% humidity and 16 °C for 3 s, and subdued in liquid ethane by plunge-freezing. For the S-6P-35B5 Fab complex, micrographs were recorded on a FEI Titan Krios (Thermo Fisher) electron microscope operated at 300 kV. Totally, 3740 movies were recorded on a K3 Summit direct electron detector (Gatan) in the super-resolution mode (0.5475 Å/pixel) at a nominal magnification of 81,000 using a defocus range of 1.2–1.3 μm. A Gif Quantum energy filter (Gatan) with a slit width of 20 eV was used on the detector. The micrographs were dose-fractionated into 32 frames with a total electron exposure of ~50 electrons per Å².

For the S-6P-32C7 Fab complex, micrographs were collected on a FEI Titan Krios (Thermo Fisher) operating at 300 kV using the AutoEMotion software. 55 Totally, 2528 movies were recorded on a K3 Summit direct electron detector (Gatan) in the super-resolution mode (0.53865 Å/pixel) at a nominal magnification of 81,000 using a defocus range of 1.4–1.8 μm. A Gif Quantum energy filter (Gatan) with a slit width of 20 eV was used on the detector. The micrographs were dose-fractionated into 32 frames with a total electron exposure of ~50 electrons per Å².

Cryo-EM image processing
Raw movie frames were binned, aligned and averaged into motion-corrected summed images using MotionCor2. 56 The dose-weighted images were then imported into cryoSPARC 57 for the following image processing, including CTF estimation, particle picking and extraction, 2D classification, ab initio 3D reconstruction, heterogeneous 3D refinement and nonuniform homogeneous refinement. For the S-6P-35B5 Fab complex, eight representative particle templates were generated in 2D classification of 65,242 particles auto-picked by the blob picker from the first 1000 micrographs. Using these templates, 1,178,527 particles were extracted with a box size of 330 × 330 and classified into 150 classes in 2D classification. Among them, 43 classes that included 818,470 particles were selected for ab initio 3D reconstruction and heterogeneous refinement. Finally, 392,378 particles reconstructed an apparent architecture of the S-6P-35B5 Fab complex and were subjected to two more rounds of ab initio 3D reconstruction and heterogeneous refinement before nonuniform refinement. Then the particles were subjected to global and local CTF refinement for final nonuniform refinement, and generated three abundant populations of the S-6P-35B5 Fab complex and structures. Local refinements of the RBD-35B5 Fab region were performed to improve the interface density in cryoSPARC. Sharpened maps were generated and validated for model building and refinement. Reported resolutions are based on the gold-standard Fourier shell correlation 58,59 of 0.143 criterion.

For the S-6P-32C7 Fab complex, four representative particle templates were generated in 2D classification of 122,851 particles auto-picked by the blob picker from the first 1000 micrographs. Based on these templates, 744,865 particles were extracted with a box size of 380 × 380 and classified into 150 2D classes. Among them, 28 classes including 338,454 particles were selected for ab initio 3D reconstruction and heterogeneous refinement. 125,858 particles that reconstructed an apparent architecture of the S-6P-32C7 Fab complex were subjected to two more rounds of ab initio 3D reconstruction and heterogeneous refinement before nonuniform refinement. Finally, the S-6P-32C7 Fab complex structure that only includes a bound 32C7 Fab was reconstructed from 119,062 particles. Local refinement of the RBD-32C7 Fab region was also performed.

Cryo-EM structure modeling and analysis
To build the S-6P-35B5 Fab complex structural model, an “up” RBD-35B5 Fab model was first generated using a Fab structure (PDB ID: 2X7L) and a RBD model from the Spike trimer (PDB ID: 7X8Y) and manually built in Coot. 60 In the locally refined map. The obtained RBD-35B5 Fab model was superimposed with the intact Spike trimer structure (PDB ID: 7X8Y) to generate an initial model of the S-6P-35B5 Fab complex model. The “down” RBD-35B5 Fab model was obtained from fitting the structures of 35B5 Fab, the RBD, and NTD domains into the locally refined map of the S-6P-35B5 Fab complex of State 1 and then validated by Phenix. 61 The model building of the S-6P-32C7 Fab complex was carried out in a similar procedure as that of the S-6P-35B5 Fab complex with a Spike trimer structure (PDB ID: 6XKL) as a template. All model building was performed in Coot. 60 Structural refinement and validation were carried out in Phenix. 61 Structural figures were generated using UCSF ChimeraX version 1.2.62

Statistics
In the mouse study assessing mAb protection against WT SARS-CoV-2, the comparisons of lung viral titers and lung cytokine/chemokine mRNA were performed using one-way ANOVA with Tukey’s post hoc test by Prism 6.0 (GraphPad). In the mouse study assessing mAb protection against SARS-CoV-2 VOCs, the comparison of lung viral titers was performed using t test (unpaired) by Prism 6.0 (GraphPad).

DATA AVAILABILITY
The data used in the study are available from the corresponding authors upon reasonable request. The cryo-EM maps and atomic coordinates have been deposited to the Electron Microscopy Data Bank (EMDB) and Protein Data Bank (PDB) with accession codes EMD-31033 and PDB 7E9N (State 1 of the 35B5 Fab-S-6P complex), EMD-31444 and PDB 7F46 (“down” RBD-35B5 Fab local refinement of State 1), EMD-
31034 and PDB 7EQ0 (State 2 of the 3SB5 Fab-S-6P complex), EMD-31035 and PDB 7EQP (up’ RBD/S3B5 Fab local refinement of State 2), EMD-31036 and PDB 7EQQ (State 3 of the 3SB5 Fab-S-6P complex), EMD-31209 and PDB 7ENF (the 32C7 Fab-S-6P complex), and EMD-31210 and PDB 7ENG (“down” RBD/32C7 Fab local refinement).

ACKNOWLEDGEMENTS

We thank Guangdong Center for Human Pathogen Culture Collection (GDPC) for providing SARS-CoV-2 isolates. We thank Dr. Junyu Xiao (Peking University) for providing the plasmids encoding the ectodomains of the SARS-CoV-2 S-2P and S-6P mutants. This work was supported by grants from the National Natural Science Foundation for Distinguished Young Scholars (No. 31825011 to L.Y.), the National Science and Technology Major Project (No. 2017ZX1020201-002-002 to L.Y.), Guangdong Innovative and Entrepreneurial Research Team Program (2016ZT056538 to K.D.), High-level Biosafety Laboratory Construction and Operation Program of the Science and Technology Projects of Guangdong Province of China to K.D., the National Natural Science Fund (81925024 to Y.Z.), the National Key Research and Development Program of China (2017YFA0503900 to Y.Z.), and the Fundamental Research Funds for the Central Universities to Y.Z.

AUTHOR CONTRIBUTIONS

X.C., Y.Z., P.Y., Y.L., J.Z., L.G., J.Z., L.X. and Q.H. collected the PBMC, isolated SARS-CoV-2 RBD-specific B cells, and cloned the antibodies; A.H., Y.Z., F.J., F.L., Y.S., F.H., X.Y., Y.P., L.T., H.Z., H.Z., J.H. and H.Z. performed in vitro and in vivo SARS-CoV-2 virus-neutralization assays; X.W. and A.L. performed negative stainings and cryo-EM analyses. X.C. and Y.Z. drafted the manuscript, which was edited by L.Y., K.D., X.W. and A.H., Y.Z., K.D. and L.Y. supervised the study. All authors have read and approved the article.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41392-022-00954-8.

Competing interests: The pending patents of 3SB5 and 32C7 have been licensed.

REFERENCES

1. Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. New. Engl. J. Med. 384, 229–237 (2021).
2. Weinreich, D. M. et al. REGEN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. New. Engl. J. Med. 384, 238–251 (2021).
3. Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. J. Am. Med. Assoc. 325, 632–644 (2021).
4. Kim, J. Y. et al. Safety, virologic efficacy, and pharmacokinetics of CT-P59, a human monoclonal antibody with pan-neutralizing activities. Science 372, 730 (2020).
5. Bok, K., Sitar, S., Graham, B. S. & Mascola, J. R. Accelerated COVID-19 vaccine development. Science 370, 725–730 (2020).
6. Wang, J. et al. Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science 372, 525–530 (2021).
7. Yorkovetskiy, L. et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183, 739–751 (2021).
8. Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Science 369, 1050 (2020).
9. Wang, P. et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host. Microbe 29, 747–751 (2021).
10. Lv, Z. et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science 369, 1505–1509 (2020).
11. Romero, P. E. et al. The emergence of SARS-CoV-2 variant lambda (C.37) in South America. Microbiol Spectr 9, e0078921 (2021).
12. Toelzer, C. et al. Free fatty acid binding pocket in the locked structure of SARS-CoV. Cell 184, 1201–1213 (2021).
13. Barman, C. et al. SARS-CoV-2 neutralizing antibodies structures inform therapeutic strategies. Nature 588, 682–687 (2020).
14. Bentzon, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327–330 (2020).
15. Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).
16. Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384–2393 (2021).
17. Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep 36, 109415 (2021).
18. Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372–2383 (2021).
19. Edara, V. V. et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell. Host. Microbe 29, 516–521 (2021).
20. yang, K. et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. New. Engl. J. Med. 384, 1468–1470 (2020).
21. Wang, Z. et al. mRNA vaccine-elicted antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622 (2021).
22. Chen, X. et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal. Transduct. Tar. 5, 180 (2020).
23. Sokal, A. et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell 184, 1201–1213 (2021).
24. Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830–833 (2020).
25. Sun, S. H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell. Host. Microbe 28, 124–133 (2020).
26. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
27. Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501–1505 (2020).
28. Du, S. et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell 183, 1013–1023 (2020).
29. Barnes, C. O. et al. SARS-CoV-2 neutralizing antibodies structures inform therapeutic strategies. Nature 588, 682–687 (2020).
30. Xu, K. et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med. 24, 857–867 (2018).
31. Kong, R. et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352, 828–833 (2016).
49. Rappazzo, C. G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. *Science* **371**, 823–829 (2021).

50. Chen, X. et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. *Cell. Mol. Immunol.* **17**, 647–649 (2020).

51. Smith, K. et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. *Nat. Protoc.* **4**, 372–384 (2009).

52. Real-Fernández, F. et al. Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization. *Anal. Bioanal. Chem.* **407**, 7477–7485 (2015).

53. Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature* **584**, 115–119 (2020).

54. Sun, J. et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. *Cell* **182**, 734–743 (2020).

55. Lei, J. & Frank, J. Automated acquisition of cryo-electron micrographs for single particle reconstruction on an FEI Tecnai electron microscope. *J. Struct. Biol.* **150**, 69–80 (2005).

56. Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat. Methods* **14**, 331–332 (2017).

57. Punjani, A., Rubinstein, J., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat. Methods* **14**, 290–296 (2017).

58. Henderson, R. et al. Outcome of the first electron microscopy validation task force meeting. *Structure* **20**, 205–214 (2012).